Een onderzoek om voortdurende toegang tot onderzoeksgeneesmiddelen te bieden aan kinderen en adolescenten die klinische onderzoeken met hiv-behandelingen van Gilead hebben afgerond
Een open-label, eenarmige studie om voortgezette toegang tot het onderzoeksgeneesmiddel te bieden aan deelnemers die pediatrische klinische onderzoeken hebben afgerond met HIV-behandelingen van Gilead
The goal of this clinical study is to provide continued access to the study drug(s) to children and adolescents with human immunodeficiency virus type 1 (HIV-1) who completed their participation in an applicable parent study and to monitor for adverse events.
The primary objectives of this study are as follows:
- To provide continued access to the study drug received in the parent protocol or switch to bictegravir/emtricitabine/tenofovir (B/F/TAF) for participants who completed a Gilead parent study evaluating drugs for HIV treatment.
- To evaluate the safety of the study drug(s) in participants with HIV-1.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
- Geneesmiddel: F/TAF (High Dose Tablet)
- Geneesmiddel: F/TAF (Low Dose Tablet)
- Geneesmiddel: F/TAF (Lowest Dose Tablet)
- Geneesmiddel: B/F/TAF (High Dose)
- Geneesmiddel: B/F/TAF (Low Dose)
- Geneesmiddel: B/F/TAF (High Dose TOS)
- Geneesmiddel: 3rd ARV Agent
- Geneesmiddel: E/C/F/TAF
- Geneesmiddel: E/C/F/TAF (Low Dose)
- Geneesmiddel: F/TAF (High Dose TOS)
- Geneesmiddel: F/TAF (Low Dose TOS)
- Geneesmiddel: F/TAF (Lowest Dose TOS)
- Geneesmiddel: Cobicistat (High Dose)
- Geneesmiddel: Cobicistat (Low Dose)
- Geneesmiddel: Cobicistat (TOS)
- Geneesmiddel: B/F/TAF (Low Dose TOS)
- Geneesmiddel: B/F/TAF (Lowest Dose TOS)
- Geneesmiddel: Nucleos(t)ide reverse transcriptase inhibitors (NRTI)
- Geneesmiddel: ATV
- Geneesmiddel: DRV
- Geneesmiddel: Lopinavir Boosted with ritonavir (LPV/r)
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 4
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Gilead Clinical Study Information Center
- Telefoonnummer: 1-833-445-3230 (GILEAD-0)
- E-mail: GileadClinicalTrials@gilead.com
Studie Locaties
-
-
-
Buenos Aires, Argentinië, C1141 ACG
- Voltooid
- Helios Salud
-
-
-
-
-
Kampala, Oeganda, 10005
- Werving
- Joint Clinical Research Centre
-
Kampala, Oeganda, 256
- Werving
- MU-JHU Research Collaboration/MU-JHU Care Ltd
-
Kampala, Oeganda
- Werving
- Baylor College of Medicine
-
Kampala, Oeganda
- Werving
- Strengthening Institutional Capacity for Research Administration (SICRA)
-
Masaka, Oeganda
- Werving
- Africa Medical and Behavioral Sciences Organisation
-
-
-
-
-
Panama City, Panama, 0816-00383
- Voltooid
- Hospital del Niño
-
-
-
-
-
Bangkok Noi, Thailand, 10700
- Actief, niet wervend
- Faculty of Medicine - Mahidol University
-
Khon Kaen, Thailand, 40002
- Actief, niet wervend
- Khon Kaen University
-
-
-
-
-
Harare, Zimbabwe
- Werving
- University of Zimbabwe Clinical Research Centre
-
-
-
-
-
Cape Town, Zuid-Afrika, 7505
- Werving
- University of Stellenbosch
-
Durban, Zuid-Afrika, 3629
- Werving
- Enhancing Care Foundation
-
Johannesburg, Zuid-Afrika, 2112
- Werving
- Rahima Moosa Mother and Child Hospital
-
Johannesburg, Zuid-Afrika, 2038
- Werving
- WITS RHI Research Centre
-
Paarl, Zuid-Afrika, 7626
- Werving
- Be Part Yoluntu Centre
-
Pretoria, Zuid-Afrika, 0087
- Werving
- The Aurun Institute
-
Soweto, Zuid-Afrika, 2013
- Werving
- Perinatal HIV Research Unit
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
- Completed an applicable parent study: GS-US-292-0106, GS-US-380-1474, GS-US-311-1269, or GS-US-216-0128, and gave consent to study participation.
Key Exclusion Criteria:
-
Individuals planning to switch to B/F/TAF on Day 1 with plasma HIV RNA ≥ 50 copies/mL during the last parent study visit prior to screening/Day 1 visit.
- Note: individuals planning to switch after Day 1 must not have plasma HIV RNA ≥ 50 copies/mL (or detectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).
-
Individuals planning to switch to B/F/TAF with any ongoing Grade 3 or 4 drug-related AE or clinically relevant Grade 3 or 4 drug-related laboratory abnormality (confirmed on repeat) related to any component of B/F/TAF prior to treatment switch.
-
For those on B/F/TAF or planning to switch to B/F/TAF: previous treatment discontinuation of any component of B/F/TAF due to toxicity or intolerance.
-
For those planning to switch to B/F/TAF: known hypersensitivity to any component of the study drug, its metabolites, or formulation excipients.
-
Ongoing treatment with or prior use of any prohibited medications.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Rollover from Parent Study: GS-US-311-1269: Parent Study Drug (F/TAF) or B/F/TAF
Participants will continue to take the study drug they were taking in the parent study, emtricitabine/tenofovir alafenamide (F/TAF) along with a 3rd antiretroviral (ARV) agent. The dose of F/TAF will be based on the weight of the participant, ranging between 120/15 mg to 200/25 mg. The dose of F/TAF will be different when given with the boosted and the unboosted 3rd ARV agent: F/TAF (High Dose Tablet) for unboosted 3rd ARV agent; F/TAF (Low Dose Tablet) for the boosted 3rd ARV agent. Participants may switch to B/F/TAF, at a dose based on participant's weight. |
200/25 mg fixed-dose combination (FDC) tablet administered orally
Andere namen:
200/10 mg FDC tablet administered orally 120/15 mg FDC tablet administered orally 50/200/25 mg FDC tablet administered orally
Andere namen:
30/120/15 mg FDC tablet administered orally
Andere namen:
15/60/7.52 mg TOS administered orally
Andere namen:
A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country |
|
Experimenteel: Rollover from Parent Study: GS-US-292-0106: Parent Study Drug (E/C/F/TAF) or B/F/TAF
Participants will continue to take the study drug they were taking in the parent study, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF). The dose of E/C/F/TAF will be based on the weight of the participant, ranging between 90/90/120/6 mg to 150/150/200/10 mg. Participants may switch to B/F/TAF at a dose based on participant's weight. |
50/200/25 mg FDC tablet administered orally
Andere namen:
30/120/15 mg FDC tablet administered orally
Andere namen:
150/150/200/10 mg tablet administered orally
Andere namen:
90/90/120/6 mg tablet administered orally |
|
Experimenteel: Rollover Parent Study GS-US-216-0128: Parent Study Drug (Combination Drugs) or B/F/TAF
Participants will continue to take the following study drugs they were taking in the parent study:
The dose of F/TAF will be based on the weight of the participant, ranging between 15/1.88 mg and 200/25 mg, once daily. Additionally, the dose of COBI will be based on the weight of the participant, ranging between 30 mg and 150 mg, once or twice daily. Participants may switch to B/F/TAF at a dose based on participant's weight. |
200/25 mg fixed-dose combination (FDC) tablet administered orally
Andere namen:
120/15 mg FDC tablet administered orally 50/200/25 mg FDC tablet administered orally
Andere namen:
30/120/15 mg FDC tablet administered orally
Andere namen:
15/60/7.52 mg TOS administered orally
Andere namen:
A 3rd antiretroviral (ARV) agent administered as defined by the investigator, according to the prescribing information. A 3rd ARV agent may include: boosted atazanavir (ATV), boosted lopinavir (LPV/r), boosted darunavir (DRV), unboosted efavirenz (EFV), unboosted nevirapine (NVP), unboosted raltegravir (RAL), or unboosted dolutegravir (DTG), or any other unspecified agent that is available in a participant's country 60/7.5 mg tablet for oral suspension (TOS) administered orally 30/3.75 mg TOS administered orally 15/1.88 mg TOS administered orally 150 mg tablet administered orally
Andere namen:
90 mg tablet administered orally
Andere namen:
30 mg TOS administered orally
Andere namen:
7.5/30/3.76 mg TOS administered orally
Andere namen:
3.76/15/1.88 mg TOS administered orally
Andere namen:
NRTIs administered as defined by the investigator, according to the prescribing information. NRTIs may include zidovudine (ZDV), stavudine (d4T), didanosine (ddI), abacavir (ABC), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), lamivudine (3TC), or emtricitabine (FTC) Administered according to the prescribing information Administered according to the prescribing information Administered according to the prescribing information |
|
Experimenteel: Rollover from Parent Studies: GS-US-380-1474 and CO-US-380-5578: Parent Study Drug (B/F/TAF)
Participants will continue to take the study drug they were taking in the parent study, B/F/TAF. Participants who are diagnosed with HIV-1 infection in parent study CO-US-380-5578 and complete the study drug will continue to take the study drug they were taking in the parent study, B/F/TAF. The dose of B/F/TAF will be based on the weight of the participant. |
50/200/25 mg FDC tablet administered orally
Andere namen:
30/120/15 mg FDC tablet administered orally
Andere namen:
15/60/7.52 mg TOS administered orally
Andere namen:
7.5/30/3.76 mg TOS administered orally
Andere namen:
3.76/15/1.88 mg TOS administered orally
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Number of Eligible Participants Who Have Received Access to the Study Drug(s) in the Study
Tijdsspanne: Up to 2.8 Years
|
Up to 2.8 Years
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Percentage deelnemers dat tijdens de behandeling optredende bijwerkingen (TEAE's) ervaart
Tijdsspanne: Tot 9,5 jaar
|
Tot 9,5 jaar
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Studie directeur: Gilead Study Director, Gilead Sciences
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Zwavelverbindingen
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Farmaceutische voorbereidingen
- Doseringsvormen
- Thiazoles
- Azoles
- Nucleïnezuren, nucleotiden en nucleosiden
- Zuren, acyclisch
- Carbonzuren
- Purines
- Deoxycytidine
- Cytidine
- Pyrimidine -nucleosiden
- Pyrimidines
- Organofosforverbindingen
- Nucleosiden
- Deoxyribonucleosides
- Organofosfonaten
- Adenine
- Drugscombinaties
- Tenofovir
- Emtricitabine
- Carbamates
- Cobicistat
- Elvitegravir, cobicistat, emtricitabine, tenofovirdisoproxilfumaraat Geneesmiddelcombinatie
- Ritonavir
- Tabletten
- Bictegravir, Emtricitabine, Tenofovir Alafenamide, combinatie van geneesmiddelen
- Emtricitabine tenofovir alafenamide
Andere studie-ID-nummers
Andere studie-ID-nummers
- GS-US-380-6684
- 2024-000521-40 (Andere identificatie: European Medicines Agency)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .